Abstract
A placebo-controlled, double-blind, randomized, parallel-group, long-term phase III trial assessing the safety and efficacy of eprotirome in patients with heterozygous familial hypercholesterolaemia (HeFH) who are on optimal standard of care. This study was investigating the efficacy of eprotirome in patients with HeFH who were receiving optimal standard of care. The primary endpoint was the percent reduction in low-density lipoprotein cholesterol from baseline to 12 weeks. The development of eprotirome was discontinued in February 2012, after dog toxicology studies revealed that 12 months of exposure to the drug led to cartilage damage, leading to termination of this trial and all other trials in the phase III programme.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kastelein J. A placebo-controlled, double-blind, randomized, parallel-group, long term phase III trial assessing the safety and efficacy of eprotirome in patients with heterozygous familial hypercholesterolaemia who are on optimal standard of care [ClinicalTrials.gov identifier NCT01410383]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2012 Mar 20]
Karo Bio. Karo Bio terminates the eprotirome program [media release]. 2012 Feb 14 [online]. Available from URL: http://www.karobio.com [Accessed 2012 Apr 16]
Angelin B, Rudling M. Lipid lowering with thyroid hormone and thyromimetics. Curr Opin Lipidol 2010 Dec 1; 21: 499–506
Tancevski I, Eller P, Patsch JR, et al. The resurgence of thyromimetics as lipidmodifying agents. Curr Opin Investig Drugs 2009; 10: 912–8
Ladenson PW. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Eng J Med 2010; 362: 906–16
Karo Bio: The New England Journal of Medicine publishes clinical results on Karo Bio’s lipid lowering drug eprotirome [media release]. 2010 Mar 11 [online]. Available from URL: http://www.karobio.com [Accessed 2012 Apr 16]
Berkenstam A. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Nat Acad Sci 2008; 105: 663–7
Ballock RT, Reddi AH. Thyroxine is the serum factor that regulated morphogenesis of columnar cartilage from isolated chondrocytes in chemically defined medium. J Cell Biol 1994; 126: 1311–8
Lewinson D, Harel Z, Shenzer P, et al. Effect of thyroid hormone and growth hormone on recovery from hypothyroidism of epiphyseal growth plate cartilage and its adjacent bone. Endocrinology 1989; 124: 937–45
Lewinson D. Differential effects of hypothyroidism on the cartilage and the osteogenic process in the mandibular condyle: recovery by growth hormone and thyroxine. Endocrinology 1994; 135: 1504–10
Adis R&D Insight database [online]. Available from URL: http://bi.adisinsight.com [Accessed 2012 Mar 27]
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sweetlove, M. Phase III Trial of Eprotirome. Pharm Med 26, 185–187 (2012). https://doi.org/10.1007/BF03262392
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03262392